An 11-Beta Hydroxysteroid Dehydrogenase Type 1 Inhibitor, JTT-654 Ameliorates Insulin Resistance and Non-obese Type 2 Diabetes
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b23-00129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Shiro Heitaku und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Pharmaceutical Research Institute, Japan Tobacco Inc. Hauptthemen laut MEDLINE: Insulin Resistance, Cortisone, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Pharmaceutical Research Institute, Japan Tobacco Inc.
Zitieren
APA
Heitaku, S., Sasase, T., Sotani, T., Maki, M., Katsumi, S., Fukuda, S., Goto, H., Yamamoto, H., & Nishiu, J. (2023). An 11-Beta Hydroxysteroid Dehydrogenase Type 1 Inhibitor, JTT-654 Ameliorates Insulin Resistance and Non-obese Type 2 Diabetes. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00129
Vancouver
Heitaku S, Sasase T, Sotani T, Maki M, Katsumi S, Fukuda S, et al. An 11-Beta Hydroxysteroid Dehydrogenase Type 1 Inhibitor, JTT-654 Ameliorates Insulin Resistance and Non-obese Type 2 Diabetes. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b23-00129
BibTeX
@article{Heitaku2023,
author = {Heitaku, Shiro and Sasase, Tomohiko and Sotani, Tomohiro and Maki, Mimi and Katsumi, Sohei and Fukuda, Sumiaki and Goto, Hiroyuki and Yamamoto, Hiroshi and Nishiu, Jun},
title = {An 11-Beta Hydroxysteroid Dehydrogenase Type 1 Inhibitor, JTT-654 Ameliorates Insulin Resistance and Non-obese Type 2 Diabetes},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b23-00129}
}
EUVIMED